AATMAJ vs ANUHPHR: Stock Comparison
ANUH PHARMA is the larger company by market capitalisation. ANUH PHARMA shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
AATMAJ leads 4; ANUHPHR leads 7 of 11
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | AATMAJ | ANUHPHR |
|---|---|---|
| Sector | — | Healthcare |
| Industry | — | Pharmaceuticals |
Price
| Metric | AATMAJ | ANUHPHR |
|---|---|---|
| Live Price | — | ₹93.66 |
| Day Change | — | 0.19% |
| Volume | — | 1.92 L |
| 52-Week High | — | ₹99.5 |
| 52-Week Low | — | ₹67 |
| Distance from 52W High | — | -5.87% |
Valuation
| Metric | AATMAJ | ANUHPHR |
|---|---|---|
| Market Cap | ₹44 Cr | ₹933 Cr |
| P/E Ratio | — | 20.86x |
| P/B Ratio | — | 2.62x |
| EPS | ₹0.32 | ₹3.58 |
| Book Value | ₹22.49 | ₹35.14 |
| Dividend Yield | 0% | 1.6% |
Growth
| Metric | AATMAJ | ANUHPHR |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 2% |
| EPS Growth (TTM YoY) | 0% | -6% |
| Qtr Sales Growth | 124.95% | -74.88% |
| Qtr Profit Growth | 39.69% | -72.17% |
Profitability & Leverage
| Metric | AATMAJ | ANUHPHR |
|---|---|---|
| ROE | 1.4% | 11.65% |
| ROCE | 2.86% | 11.96% |
| Net Margin | 0% | 5.32% |
| Operating Margin | 9.66% | 7.09% |
| Debt to Equity | 0.41x | 0x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | AATMAJ | ANUHPHR |
|---|---|---|
| Promoter Holding | 64.33%▲ 0.57 pp | 71.78% |
| FII Holding | 0% | 0.01%▼ 0.04 pp |
| DII Holding | 0% | 0% |
| Public Holding | 35.67%▼ 0.57 pp | 28.19%▲ 0.03 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AATMAJ and ANUH PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.